eLife, BioMed Central (BMC), the Public Library of Science (PLoS), and the European Molecular Biology Organization (EMBO) will be forming a new peer review consortium based around the concept of what eLife calls “portable peer review.”
Most publishers offering delayed free access to journal articles set their embargo period more than a decade ago. Is it time to revisit the access embargo?
After wondering at the supposed burden of peer-review, more evidence emerged that it still works well, and is probably less taxing than other alternatives.
EMBO opens up the black box of peer-review. Is it worth the cost?